Learn More
A phase I trial of the combination of irinotecan (CPT-11) with cisplatin in advanced non-small cell lung cancer (NSCLC) showed a very promising response rate of 54% in previously untreated NSCLC patients. This study was conducted to confirm the activity and toxicities of CPT-11 and cisplatin combination for previously untreated NSCLC in a(More)
The purpose of this study was to evaluate the efficacy and safety of a novel oral anticancer fluoropyrimidine derivative, S-1, in patients receiving initial chemotherapy for unresectable, advanced non-small-cell lung cancer (NSCLC). Between June 1996 and July 1998, 62 patients with NSCLC who had not received previous chemotherapy for advanced disease were(More)
To determine a standard combination chemotherapy for patients with advanced non-small-cell lung cancer (NSCLC), we conducted a phase III trial of irinotecan (CPT-11) to test the hypotheses that CPT-11+cisplatin is superior to cisplatin+vindesine and that CPT-11 monotherapy is not inferior to cisplatin+vindesine. A total of 398 patients with previously(More)
NUMEROUS STUDIES have revealed that bacterial adjuvants such as BCoG and BCG cell-wall skeletons have strong anti-tumour activity for animal tumours and also for human malignancies (Ogura et al., 1978; Sarna et al., 1978; Yamamura et al., 1979). These bacterial adjuvants are presumed to activate mainly macrophages and lymphocytes, and render them toxic(More)
We performed MRI on 57 socially active, healthy people without neurologic signs or symptoms when admitted to our hospital for a routine medical evaluation. Of these, 34 persons had patchy white matter lesions (PWMLs). Mild lesions were distributed mainly around the anterior horns or the bodies of the lateral ventricles. However, more severe lesions were(More)
  • 1